Colorectal Cancer

I have read the CME Disclosures

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through Joint Sponsorship of Cin�-Med and the Angiogenesis Foundation. Cin�-Med is accredited by the ACCME to provide continuing medical education for physicians.

Cin�-Med designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits�. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit will be awarded provided this activity is used and completed according to instructions and a score of 70% or better is achieved. A certificate of credit will be issued to those who successfully complete the examination.

Date of original release: February 1, 2013
Date of expiration: January 31, 2014
CME Course Code: 2013CRC

Practicing oncologists and primary care physicians in the U.S., researchers and medical students

Colorectal cancer is the third most commonly diagnosed cancer and the third leading cause of cancer death in both men and women.

Three critical needs have been identified by the Angiogenesis Foundation in regards to colorectal cancer. There is a large amount of new information emerging on colorectal cancer therapies and clinicians do not have enough time to adequately review all of this important information in this rapidly expanding field. Clinicians are not educating patients about the side effects of antiangiogenic therapy and referring patients to specialists to optimize management of side effects and increasing patient outcomes. There are many clinical trials out there researching several new targeted therapies, providing clinicians with this updated information will help increase enrollment in these clinical trials and can lead to an increase in the number of treatment options with fewer side effects.

New treatment approaches are therefore urgently required to improve outcome in this disease and one promising strategy to have emerged has been the study of angiogenesis in colorectal cancer and the role of modulators of angiogenesis in its treatment.

At the completion of this activity, participants should be able to:

  • Describe the role of tumor angiogenesis as both a disease mechanism and therapeutic target in mCRC.
  • Explain how antiangiogenic therapies may be integrated into current mCRC treatment regimens, including front-line, second-line, maintenance, and adjuvant therapy settings.
  • Discuss clinical efficacy and safety data from recent studies on antiangiogenic therapies for mCRC.
  • Describe common safety concerns of antiangiogenic cancer therapy and their management.
  • Explain strategies for addressing progressive disease, including the use of combination antiangiogenic treatment or new therapy targets under investigation.

This activity is designed to address the following ABMS / IOM competencies:
Patient Care and Medical Knowledge

There are no fees for participating in and receiving credit for this online educational activity. The participant should, in order, read the objectives and faculty disclosures, review the educational content, answer the multiple-choice post-test and complete the evaluation. This program is available in PDF format accessible from the Angiogenesis Foundation's website ( in the CME section. A print version is also available; for more information contact After reviewing the material, CME credits are available through the Angiogenesis Foundation's website ( by selecting the name of the program (registration required). Course code: 2013CRC

This activity is supported by an educational grant from Sanofi-Aventis and Regeneron.

William Li, MD
Dartmouth Medical College

Cin�-Med asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Cin�-Med has procedures to resolve apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

William W. Li, M.D.
President, the Angiogenesis Foundation, Editor-in-Chief
Dr. Li has nothing to disclose with regard to commercial interests.

Erin Grothey, M.S.
Medical writer.
Medical Writer has no relevant financial relationships to disclose. Erin Grothey's spouse received grant/research support from Genentech and Eli Lilly and Company.

All Cine-Med and Angiogenesis Foundation employees in control of content have indicated that they have no relevant financial relationships to disclose.

This CME activity contains discussion of published and/or investigational use of: aflibercept, Axitinib, bevacizumab, BIBF 1120, brivanib, cediranib, CT-322, Dovitinib, EMD 525797, IMC-18F1, MEGF0444A, MK-2206, Ornatuzumab, ramucirumab, regorafenib, sorafenib, sunitinib, Tas-102, and Tivozanib.

Antiangiogenic therapy for locally advanced colorectal cancer:

  • FDA Approved Antiangiogenic Agents for CRC
  • Antiangiogenic Agents in Clinical Development for CRC
  • Biomarkers for Anti-Angiogenic Therapy in Colorectal Cancer
  • Antiangiogenic Escape Mechanisms and Clinical Management
  • Antiangiogenic Combination Strategies for Colorectal Cancer
  • Side Effects
  • Future directions

This educational program is available in PDF format. To view and print PDF files, you must have Adobe Reader installed on your computer. Most computers already have this software installed. If yours does not, you can download Adobe Reader free from the Adobe Web site:

For questions about this program, please contact the Angiogenesis Foundation at 617-401-2779 or